Alnylam Pharmaceuticals, Inc.
ALNY
Rang in Aktien
#776
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily... Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Aktienkurs
$233.11
Marktkapitalisierung
$31.19B
Veränderung (1 Tag)
0.55%
Veränderung (1 Jahr)
-51.60%
Land
US
Handel Alnylam Pharmaceuticals, Inc. (ALNY)
Kategorie
Healthcare
Operative Marge für Alnylam Pharmaceuticals, Inc. (ALNY)
Operative Marge zum October 2026 TTM: 20.81%
Laut den neuesten Finanzberichten und dem Aktienkurs von Alnylam Pharmaceuticals, Inc. beträgt die aktuelle operative Marge (TTM) 20.81%. Am Ende des Jahres 2023 lag die operative Marge bei -15.43%.
Historie der operativen Marge von Alnylam Pharmaceuticals, Inc. von 2002 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 20.81% | -364.42% |
| 2024 | -7.87% | -49.00% |
| 2023 | -15.43% | -79.61% |
| 2022 | -75.68% | -9.83% |
| 2021 | -83.93% | -50.07% |
| 2020 | -168.09% | -60.68% |
| 2019 | -427.50% | -60.69% |
| 2018 | -1,087.56% | 95.53% |
| 2017 | -556.20% | -38.22% |
| 2016 | -900.33% | 25.00% |
| 2015 | -720.27% | -10.08% |
| 2014 | -800.97% | 306.48% |
| 2013 | -197.05% | 1.57% |
| 2012 | -194.01% | 192.89% |
| 2011 | -66.24% | 50.37% |
| 2010 | -44.05% | -7.96% |
| 2009 | -47.86% | 65.32% |
| 2008 | -28.95% | -84.19% |
| 2007 | -183.07% | 24.81% |
| 2006 | -146.68% | -80.71% |
| 2005 | -760.53% | 0.84% |
| 2004 | -754.18% | -94.70% |
| 2003 | -14,236.93% | 0.00% |
| 2002 | 0.00% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -98.15% |
US
|
|
| -149.01% | -107.16% |
US
|
|
| 25.57% | -98.77% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.62% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.